InsidersTradesSigma
Track the Rani Therapeutics Holdings, Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Rani Therapeutics Holdings, Inc. has recorded 94 insider filings. Market capitalisation: €122.4m. The latest transaction was filed on 23 July 2026 (Acquisition). Among the most active insiders: South Cone Investments Limited Partnership. All data is openly available.
94
Insider Decl.
n/a
Thresholds
€14m
55 ops.
Buy Volume
€23m
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Rani Therapeutics Holdings, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$7.50.
52Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 July 2026
Declarations94 total
36,000 shares@ US$0.690.026% mcap1.2% of flowClass A Common StockSEC:0001031686-26-000006:0
Canonical exit: 19 Oct 2026 (T+90)
309 shares@ US$0.740.0002% mcap43.5% of flowClass A Common StockSEC:0002123843-26-000008:1
8,014 shares@ US$1.415.2% of flowClass A Common StockSEC:0001869579-26-000006:0
9,076 shares@ US$0.552.1% of flowClass A Common StockSEC:0001869579-26-000006:1
9,077 shares@ US$0.481.8% of flowClass A Common StockSEC:0001869579-26-000006:2
7,906 shares@ US$1.404.5% of flowClass A Common StockSEC:0001869579-26-000006:3
9,099 shares@ US$0.813.1% of flowClass A Common StockSEC:0001869579-26-000006:5
7,927 shares@ US$0.740.0062% mcap2.5% of flowClass A Common StockSEC:0001869579-26-000006:6
35,000 shares@ US$0.71980.026% mcap10.6% of flowClass A Common StockSEC:0001869579-26-000007:0
Canonical exit: 15 Oct 2026 (T+90)
386 shares@ US$0.7856.5% of flowClass A Common StockSEC:0002123843-26-000008:0
8,916 shares@ US$1.134.2% of flowClass A Common StockSEC:0001869579-26-000006:4
2,083,334 shares@ US$0.60559.7% of flowClass A Common StockSEC:0001031686-25-000004:0
Canonical exit: 21 Jan 2026 (T+90)
1,923,000 shares@ US$2.411517.6% of flowClass A Common StockSEC:0001104659-25-101613:0
17,960 shares@ US$1.67100.0% of flowClass A Common StockSEC:0000950170-24-136787:0
Canonical exit: 13 Mar 2025 (T+90)
10,296 shares@ US$1.9413.7% of flowClass A Common StockSEC:0000950170-24-134828:0
Canonical exit: 9 Mar 2025 (T+90)
3,305,622 shares@ US$2.552141.5% of flowClass A Common StockSEC:0001104659-24-109543:0
5,265,165 shares@ US$2.0151.9% of flowClass A Common StockSEC:0001104659-23-124719:0
Canonical exit: 22 Feb 2024 (T+90)
5,265,165 shares@ US$2.0196.5% of flowClass A Common StockSEC:0001104659-23-124723:0
10,000 shares@ US$2.2715.3% of flowClass A Common StockSEC:0000950170-23-068864:0
Canonical exit: 5 Mar 2024 (T+90)
5,000 shares@ US$2.578.6% of flowClass A Common StockSEC:0000950170-23-068442:0
Canonical exit: 3 Mar 2024 (T+90)
20,000 shares@ US$2.0527.0% of flowClass A Common StockSEC:0000950170-23-067149:0
Canonical exit: 27 Feb 2024 (T+90)
50,500 shares@ US$2.0296100.0% of flowClass A Common StockSEC:0000950170-23-065474:0
Canonical exit: 15 Feb 2024 (T+90)
500 shares@ US$1.98100.0% of flowClass A Common StockSEC:0000950170-23-064982:0
Canonical exit: 14 Feb 2024 (T+90)
2,500 shares@ US$1.983.4% of flowClass A Common StockSEC:0000950170-23-062001:0
Canonical exit: 5 Feb 2024 (T+90)
2,610 shares@ US$3.86830.0% of flowClass A Common StockSEC:0001104659-23-060817:0
Canonical exit: 9 Aug 2023 (T+90)
25 of 94 declarations
关于 Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. 是一家在美国纳斯达克市场（美国）上市的生物技术公司，专注于传统上通过注射或输注给药的生物制剂和药物的口服递送。该公司的核心理念是，通过其专有的 RaniPill 平台，许多高价值疗法可以转化为对患者友好的口服治疗。RaniPill 是一种可吞服的胶囊，旨在在小肠中精确释放剂量。从股权角度来看，这使得 Rani 处于临床阶段的平台生物技术类别：它尚未成为一家成熟的商业制药公司，而是一家开发具有多种治疗领域选择性的赋能技术的公司。（[ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/?utm_source=openai)） Rani Therapeutics 围绕差异化的药物递送概念和广泛的知识产权组合而建立。其总部位于加利福尼亚州圣何塞，将公司锚定在美国最成熟的生物技术集群之一。该公司的发展战略是证明 RaniPill 可以可靠地口服递送复杂的生物制剂，可能取代皮下注射并提高依从性、便利性和患者体验。该公司的投资者材料描述了几项支持该平台安全性、耐受性和生物利用度特征的临床前和临床研究。（[ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/?utm_source=openai)） 在运营方面，Rani 的业务线围绕平台开发、临床前验证、临床推进和战略合作。该公司并非依赖单一资产，而是试图将 RaniPill 确立为多种分子的可重复递送技术。最近的披露显示，该公司越来越关注代谢疾病和其他生物制剂密集型类别。2026 年 3 月，Rani 报告了临床前数据，显示成功口服递送司美格鲁肽，以及 RT-114（一种双特异性 GLP-1/GLP-2 双重激动剂）的临床前生物等效性数据。该公司还与 ProGen 合作启动了 RT-114 治疗肥胖症的 1 期研究。（[nasdaq.com](https://www.nasdaq.com/press-release/rani-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results?utm_source=openai)） 从竞争角度来看，Rani 在一个要求严苛的领域运营，成功取决于临床证据、可制造性、监管执行以及吸引制药合作伙伴的能力。其主要竞争优势是将可注射生物制剂转化为口服药物的潜力，如果大规模复制，这一提议可能具有高度颠覆性。尽管如此，该公司仍然面临临床阶段生物技术公司的常见风险：执行风险、监管不确定性以及持续资本获取的需求。2025 年 11 月，Rani 宣布与 Chugai Pharmaceutical 达成一项潜在价值高达 1.085 billion 美元的合作，并完成了 60.3 million 美元的超额认购私募。该公司还表示，其现金流预计将延长至 2028 年，这对一家商业化前生物技术公司来说是一个重要的进展。（[nasdaq.com](https://www.nasdaq.com/press-release/rani-therapeutics-reports-third-quarter-2025-financial-results-provides-corporate?utm_source=openai)） 对于国际投资者而言，Rani Therapeutics 最好被视为医疗保健和制药领域中一个高风险、高回报的平台故事。关键的监测点是临床结果、合作伙伴势头以及公司将其技术转化为更广泛的管线并最终实现商业价值的能力。其纳斯达克上市和美国总部是核心参考点，但投资案例最终将取决于 RaniPill 是否能成为生物制剂的可扩展递送标准。（[nasdaq.com](https://www.nasdaq.com/press-release/rani-therapeutics-reports-third-quarter-2025-financial-results-provides-corporate?utm_source=openai)）
